tradingkey.logo
搜尋

Telomir Pharmaceuticals Inc

TELO
添加自選
1.260USD
-0.010-0.79%
收盤 05/15, 16:00美東報價延遲15分鐘
86.66M總市值
虧損本益比TTM

Telomir Pharmaceuticals Inc

1.260
-0.010-0.79%
查看詳細走勢圖
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

-0.79%

5天

-3.08%

1月

-5.97%

6月

-6.67%

今年開始到現在

-5.26%

1年

-49.60%

TradingKey Telomir Pharmaceuticals Inc股票評分

單位: USD 更新時間: 2026-05-15

操作建議

Telomir Pharmaceuticals Inc當前公司基本面數據相對非常健康,最新ESG揭露屬於行業領先水平。增長潛力很大。當前估值合理,在藥品行業排名119/155位。機構持股佔比非常高,近一月多位分析師給出公司評級為。最高目標價為15.50。中期看,股價處於上升通道。近一個月,市場表現較差,但基本面評分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Telomir Pharmaceuticals Inc評分

相關信息

行業排名
119 / 155
全市場排名
474 / 4482
所屬行業
藥品

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
中性

Telomir Pharmaceuticals Inc亮點

亮點風險
Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company. The Company is focused on the development of Telomir-1, a novel small molecule metal ion chelator and regulator designed to lengthen the DNA’s protective telomere caps, which are crucial in the aging process. Telomir 1 is being developed to protect stem cells by elongating and stimulating the telomeres to sustain self-renewal. Telomir-1 helps protect against age-related conditions, including Progeria (a rare genetic disorder that causes rapid aging in children), Wilson’s disease (a genetic disorder leading to toxic copper buildup in the body), and age-related macular degeneration (AMD), as well as Type 2 Diabetes, cancer, and Alzheimer’s disease. It is exploring the potential of Telomir-1 with ongoing research in animals and then in humans. It is focused on developing and commercializing TELOMIR-1, proposed to be dosed orally, with the aim of promoting longevity and enhancing overall quality of life.
估值合理
公司最新PE估值-4.43,處於3年歷史合理位
機構加倉
最新機構持股3.42M股,環比增加12.50%
PRFDX持倉
明星投資者PRFDX持倉,最新持倉1.38K股

分析師目標

基於 0 分析師
--
評級
15.500
目標均價
+1120.47%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Telomir Pharmaceuticals Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Telomir Pharmaceuticals Inc簡介

Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company. The Company is focused on the development of Telomir-1, a novel small molecule metal ion chelator and regulator designed to lengthen the DNA’s protective telomere caps, which are crucial in the aging process. Telomir 1 is being developed to protect stem cells by elongating and stimulating the telomeres to sustain self-renewal. Telomir-1 helps protect against age-related conditions, including Progeria (a rare genetic disorder that causes rapid aging in children), Wilson’s disease (a genetic disorder leading to toxic copper buildup in the body), and age-related macular degeneration (AMD), as well as Type 2 Diabetes, cancer, and Alzheimer’s disease. It is exploring the potential of Telomir-1 with ongoing research in animals and then in humans. It is focused on developing and commercializing TELOMIR-1, proposed to be dosed orally, with the aim of promoting longevity and enhancing overall quality of life.
公司代碼TELO
公司Telomir Pharmaceuticals Inc
CEOAminov (Erez)
網址https://telomirpharma.com/
KeyAI